Imagion Biosystems Overview
- Status
-
Public
- Employees
-
19
- Stock Symbol
-
IBX
Imagion Biosystems General Information
Description
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Contact Information
Website
www.imagionbiosystems.comCorporate Office
- 385 Bourke Street, Level 11
- Suite 2
- Melbourne, Victoria 3000
- Australia
Corporate Office
- 385 Bourke Street, Level 11
- Suite 2
- Melbourne, Victoria 3000
- Australia
Imagion Biosystems Timeline
Imagion Biosystems Stock Performance
As of 19-Nov-2026, Imagion Biosystems’s current market cap is $2.71M with 803M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.71M | 803M | 2.45M |
Imagion Biosystems Financials Summary
As of 30-Sep-2026, Imagion Biosystems has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,685 | 9,757 | 4,626 | 11,572 |
| Revenue | 765 | 908 | ||
| EBITDA | (2,246) | (358) | (6,791) | |
| Net Income | (2,777) | (1,363) | (8,279) | |
| Total Assets | 1,368 | 1,743 | 3,125 | |
| Total Debt | 1,717 | 1,647 | 4,114 |
Imagion Biosystems Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Imagion Biosystems Patents
Imagion Biosystems Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200187822-A1 | Detection, measurement, and imaging of cells using cellular internalization of nanoparticles | Inactive | 15-Dec-2018 | ||
| US-20170210773-A1 | Synthesis of metal carboxylate compounds | Inactive | 02-Jun-2014 | ||
| WO-2015187544-A1 | Synthesis of metal carboxylate compounds | Inactive | 02-Jun-2014 | ||
| US-20150293004-A1 | Viscosity measuring method | Inactive | 01-Mar-2011 | ||
| US-20130090545-A1 | Methods and apparatuses for the localization and treatment of cancer | Inactive | 08-Jun-2010 | A61B5/05 |
Imagion Biosystems Signals
Imagion Biosystems ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Imagion Biosystems FAQs
-
Where is Imagion Biosystems headquartered?
Imagion Biosystems is headquartered in Melbourne, Australia.
-
What is the size of Imagion Biosystems?
Imagion Biosystems has 19 total employees.
-
What industry is Imagion Biosystems in?
Imagion Biosystems’s primary industry is Diagnostic Equipment.
-
Is Imagion Biosystems a private or public company?
Imagion Biosystems is a Public company.
-
What is Imagion Biosystems’s stock symbol?
The ticker symbol for Imagion Biosystems is IBX.
-
What is the current market cap of Imagion Biosystems?
The current market capitalization of Imagion Biosystems is $2.71M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process